Weirui Tan

Weirui Tan

Auto-generated profile, based on publicly available information

Weirui Tan

University of Massachusetts Amherst

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 December 2019 in Lab on a Chip
Verified
Journal Article
Closed access
PDF file
WTWeirui Tan
Weirui Tan
LZLiyuan Zhang
Liyuan Zhang
JDJames C. G. Doery
James C. G. Doery
WSWei Shen
Wei Shen
More than 60% newborns experience hyperbilirubinemia and jaundice within the initial week after birth due to the accumulation of total bilirubin in blood.

1 May 2021 in Sensors and Actuators B: Chemical
Verified
Journal Article
Closed access
WTWeirui Tan
Weirui Tan
EPEmma Powles
Emma Powles
LZLiyuan Zhang
Liyuan Zhang
WSWei Shen
Wei Shen

11 March 2022 in Analytica Chimica Acta
Verified
Journal Article
Closed access
PZPeng Zheng
Peng Zheng
SKSujan Kasani
Sujan Kasani
WTWeirui Tan
Weirui Tan
JBJennifer Boryczka
Jennifer Boryczka
XGXuefei Gao
Xuefei Gao
NWNianqiang Wu
Nianqiang Wu


20 November 2017 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
WTWeirui Tan
Weirui Tan
LZLiyuan Zhang
Liyuan Zhang
WSWei Shen
Wei Shen

26 August 2024 in ACS Omega
Verified
Journal Article
Open access
WTWeirui Tan
Weirui Tan
YHYingjie Hang
Yingjie Hang
AWAnyang Wang
Anyang Wang
JWJiacheng Wang
Jiacheng Wang
JWJane G. Wigginton
Jane G. Wigginton
NWNianqiang Wu
Nianqiang Wu
Paper lateral flow immunoassays combined with surface-enhanced Raman scattering (SERS) technology have gained increasing attention due to their high sensitivity characteristics resulting from the amplified SERS signals of the plasmon-enhanced optical probes. In contrast to conventional colorimetric lateral flow strips, SERS paper lateral flow strips (SERS-PLFSs) are currently not commercially available for widespread use. Analytical validation is the key step for commercialization. In this work, we have developed a PLFS with a hierarchical SERS probe (gold–silver nanoparticle@Raman reporter@silica) for detection of the US Food and Drug Administration (FDA)-approved traumatic brain injury (TBI) protein biomarker, ubiquitin C-terminal hydrolase-L1 (UCH-L1), in blood plasma samples. Analytical validation has been performed on this SERS-PLFS in terms of the limit of detection (LOD), limit of quantification (LOQ), accuracy, precision, selectivity, and stability. The SERS-PLFS exhibits a reportable range of 0.2–100 ng/mL with a LOD of 0.08 ng/mL toward measurement of UCH-L1 in blood plasma. The SERS-PLFS has been applied to clinical TBI samples. The test results were compared with those from enzyme-linked immunosorbent assay (ELISA), demonstrating a strong correlation between the two analytical methods. This study has important implications in the commercialization of SERS-PLFSs for rapid TBI detection in clinical practice.